<DOC>
	<DOCNO>NCT00226941</DOCNO>
	<brief_summary>1 . To determine MTD DLTs oxaliplatin capecitabine combine C225 radiotherapy ( Phase I ) 2 . To determine pathologic response rate C225 combination neoadjuvant cytotoxic regimen ( Phase II )</brief_summary>
	<brief_title>Safety Study Cetuximab Combination With Oxaliplatin , Capecitabine , Radiation Therapy Followed Surgery Locally-advanced Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients histologically confirm adenocarcinoma rectum : EUS stage T3 T4 N1 disease eligible ( include T3 N0 , T3 N1 , T4 N0 , T4 N1 , T14 N1 ) . Rectal cancer define whose distal border extends within 12cm anal verge . Age &gt; = 18 . Karnofsky performance status &gt; = 70 . Creatinine within normal institutional limit creatinine clearance &gt; 60mL/min/1.73m2 patient serum creatinine level institutional normal . Negative urine pregnancy test woman child bear potential ( WOCBP ) . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour prior start study medication . WOCBP must use adequate method contraception avoid pregnancy throughout treatment . Ability swallow pill without difficulty . No prior pelvic whole abdominal radiotherapy . Patients must adequate organ marrow function define : Leukocyte count &gt; 3,500 . Platelet count &gt; 100,000 . SGOT , SGPT , Alk . Phos : &lt; 2.5x institutional upper limit normal . Total bilirubin &lt; 1.5x institutional normal institutional limit . Metastatic ( M1 ) stage IV disease . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Patients concurrent malignancy previous malignancy within 5 year screen exclude study ; exception patient concurrent previous nonmelanoma skin cancer , hematolymphoid malignancy carcinoma insitu cervix , may include investigator 's discretion . WOCBP pregnant breastfeeding . A history C225 therapy target EGF receptor . A history prior anticancer murine monoclonal antibody therapy . Inability sign write consent . WOCBP unwilling unable use acceptable method avoid pregnancy entire study period 4 week study . Subjects men must also agree use effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>